iSpecimen Buys Two AI Tools From Foldlab
The $4.5 million acquisition adds AI systems for identifying disease-linked proteins and predicting disease trends to iSpecimen's biospecimen marketplace.
Updated on Nov. 5, 2026 in Biotech
iSpecimen, an online marketplace connecting scientists with biospecimen providers, completed its acquisition of two AI products from Foldlab AI Ltd. on November 2, 2026. The aggregate purchase price is $4.5 million, paid in cash, milestone payments and common stock.
Why it matters
The deal extends iSpecimen beyond sample sourcing into AI-driven research tools aimed at identifying promising protein targets and tracking disease trends. Its stock-heavy structure also ties Foldlab to iSpecimen's future performance.
The two products are an AI agent that identifies disease-associated proteins and an AI model that predicts and monitors disease trends, with iSpecimen acquiring the full software, source code, model weights, documentation and data rights. The deal includes $750,000 in cash at closing, up to $1.25 million in two $625,000 milestone payments and 2,907,977 common shares subject to a five-year lock-up.
The players
iSpecimen
iSpecimen is an online marketplace that connects scientists with biospecimen providers to support biomedical research.
Foldlab AI Ltd.
Foldlab AI Ltd. is a British Columbia-based company that developed the AI agent and predictive model sold to iSpecimen.
The details
Under an Asset Purchase Agreement dated September 4, 2026 and approved by iSpecimen stockholders on October 9, 2026, iSpecimen acquired the technology stack behind both products, including intellectual property. The shares were issued to Foldlab on November 5, 2026 in a private placement under Regulation S and Section 4(a)(2) of the Securities Act of 1933, and are subject to a voting rights agreement.
Timeline
September 4, 2026: Asset Purchase Agreement dated.
October 9, 2026: iSpecimen stockholders approved the acquisition.
November 2, 2026: Acquisition completed.
November 5, 2026: Shares issued to Foldlab.
The Tech Race
Biomedical research is increasingly pairing large sample repositories with AI analysis tools to speed target discovery. iSpecimen's purchase of protein-identification software follows this pattern of data-plus-model integration in life sciences.
Researchers using iSpecimen's marketplace may gain access to AI tools for identifying protein targets and tracking disease trends alongside biospecimen sourcing. The deal's pricing and availability for individual users have not been described.
The takeaway
Combining specimen access with AI analysis is a growing approach in biomedical research. Readers following life sciences deals can watch whether iSpecimen's new tools translate into measurable research outcomes.
Further reading
Explore more Biotech developments shaping drug discovery and research tools.
Source note: This article includes information reported by Sudbury Star.
